Heteroaromatic compounds as BTK inhibitors

A compound of the formula (I)

• Cy is phenyl, pyrazolyl, pyridinyl, pyrrolyl, imidazolyl, thiazolyl, furanyl, oxazolyl, isoxazolyl, thienyl, pyridazinyl, pyrimidinyl, pyrazinyl or pyranyl each is substituted by R1 and optionally substituted by halogen, halo C1-4 alkyl, C1-4 alkyl and C1-4 alkoxy;
• R1 is chosen from:
• L-Ar and —S(O)m—R3, each R1 is optionally substituted by Br, C1-4 alkyl, R3—S(O)2—, —CN, —C(O)—NH(R3) and C1-3 alkoxy;
• L is a linker chosen from a bond, O, >C(O), —(CH2)n—, —O—(CH2)n—, —N(R3)—, —N(R3)—(CH2)n—, —(CH2)n—N(R3)—, —C(O)—N(R3)—, —C(O)—N(R3)—(CH2)n—, —N(R3)—C(O)—N(R3)—, —N(R3)—C(O)—, —S(O)m—N(R3)—, R3—S(O)m—, and —N(R3)—S(O)m—, wherein the —CH2— in each L can have 1-2 hydrogens replaced by C1-3 alkyl, said C1-3 alkyl groups can optionally cyclize to form a C3-6 cycloalkyl ring;
• Ar is phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, indolyl, isoindolyl, benzofuranyl, benzimidazolyl, benzothiazolyl, piperidinyl, piperazinyl or pyrrolidinyl;
• Ring A of the formula (I) is an N-linked heterocycle chosen from C5-C10 spirocycle and a nitrogen containing optionally bridged mono- or bi-cyclic heterocycle, each Ring A is substituted by one Y and optionally substituted by halogen, halo C1-4 alkyl, C1-4 alkyl and C1-4 alkoxy;
• Y is —(CH2)n—N(R3)—R4, or Y is R4;
• R4 is
• wherein R5 cannot be hydrogen
• each n is independently 1-4;
• each m is independently 0-2;
• each R2 and R3 are independently chosen from hydrogen or C1-4 alkyl;
• each R5 is independently chosen from hydrogen, halogen, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylC1-4alkoxy, C1-4alkylhydroxy, —(CH2)n-heterocycle and heterocycle each heterocycle optionally substituted by halogen, OH or R2—S(O)m—;
• each group defined above for Cy, R1—R5, and Y can be where possible partially or fully halogenated;
• or a pharmaceutically acceptable salt thereof.